Factors Contributing to Risk of Persistence of Positive and Negative Symptoms in Schizophrenia during Hospitalization.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101238455 Publication Model: Electronic Cited Medium: Internet ISSN: 1660-4601 (Electronic) Linking ISSN: 16604601 NLM ISO Abbreviation: Int J Environ Res Public Health Subsets: MEDLINE

Original Publication: Basel : MDPI, c2004-

Schizophrenia*/diagnosis ; Alcoholism*; Humans ; Aged ; Magnetic Resonance Imaging ; Septum Pellucidum/pathology ; Hospitalization

The aim of the study was to evaluate factors that may contribute to the persistence of positive, negative and other psychopathological symptoms of schizophrenia. All patients were treated in general psychiatric wards between January 2006 and December 2017. The initial study sample comprised of the medical reports of 600 patients. The main, specified inclusion criterion for the study was schizophrenia as a discharge diagnosis. Medical reports of 262 patients were excluded from the study due to no neuroimaging scans being available. The symptoms were categorised into three groups: positive, negative, and other psychopathological symptoms. The statistical analysis comprised modalities such as demographic data, clinical symptoms, as well as neuroimaging scans linking them to a potential impact of sustaining the mentioned groups of symptoms during the period of hospitalization. The analysis revealed that statistically significant risk factors of persistence of the three groups of symptoms are the elderly age, the increasing toll of hospitalizations, suicidal attempts in medical history, a family history of alcohol abuse, the presence of positive, negative and other psychopathological symptoms on admission to the hospital, as well as the absence of cavum septi pellucidi (CSP). The study showed that addiction to psychotropic drugs and a family history of schizophrenia were more frequent in patients with persistent CSP.

Schizophr Res. 2008 Jul;102(1-3):1-18. (PMID: 18514488)
Arch Gen Psychiatry. 2003 Jun;60(6):585-94. (PMID: 12796222)
Pediatr Neurol. 1990 Nov-Dec;6(6):391-4. (PMID: 1705800)
AJR Am J Roentgenol. 1989 Feb;152(2):353-60. (PMID: 2783514)
J Neuropsychiatry Clin Neurosci. 2020 Spring;32(2):175-184. (PMID: 31266410)
Br J Psychiatry. 1987 Aug;151:145-51. (PMID: 3690102)
Schizophr Bull. 2018 Oct 17;44(6):1195-1203. (PMID: 29762765)
Postgrad Med J. 1987 Dec;63(746):1021-4. (PMID: 3330234)
Neuroradiology. 2010 Jun;52(6):447-77. (PMID: 20422408)
Schizophr Bull. 2016 Nov;42(6):1316-1319. (PMID: 27033328)
Psychiatry Res. 1997 Jul 4;74(3):129-40. (PMID: 9255858)
Curr Dir Psychol Sci. 2010 Aug;19(4):255-259. (PMID: 22557707)
Psychiatry Res Neuroimaging. 2017 Aug 30;266:10-18. (PMID: 28549318)
J Clin Psychiatry. 2002 Dec;63(12):1121-8. (PMID: 12523871)
P T. 2014 Sep;39(9):638-45. (PMID: 25210417)
Biol Psychiatry. 2006 Jun 15;59(12):1116-27. (PMID: 16631126)
Schizophr Res. 2009 May;110(1-3):1-23. (PMID: 19328655)
Schizophr Bull. 2009 Mar;35(2):383-402. (PMID: 19011234)
J Psychiatr Res. 2010 May;44(7):421-8. (PMID: 19878956)
PLoS Med. 2005 May;2(5):e141. (PMID: 15916472)
J Comp Neurol. 1968 Jan;132(1):45-72. (PMID: 5293999)
Surg Radiol Anat. 1999;21(2):119-23. (PMID: 10399212)
Am J Psychiatry. 2013 Jun;170(6):609-15. (PMID: 23558429)
Prog Mol Biol Transl Sci. 2018;158:195-226. (PMID: 30072054)
Schizophr Bull. 2010 Mar;36(2):359-69. (PMID: 18644851)
Schizophr Bull. 2006 Apr;32(2):250-8. (PMID: 16221995)
Biol Psychiatry. 1999 Oct 1;46(7):908-20. (PMID: 10509174)
Dialogues Clin Neurosci. 2010;12(3):271-87. (PMID: 20954425)
Schizophr Res. 2013 Aug;148(1-3):117-21. (PMID: 23756298)
Am J Psychiatry. 2005 Aug;162(8):1483-93. (PMID: 16055769)
Am J Psychiatry. 1985 Nov;142(11):1272-7. (PMID: 4061685)
Arch Gen Psychiatry. 1982 Jul;39(7):789-94. (PMID: 7165478)
Int J Environ Res Public Health. 2023 Mar 05;20(5):. (PMID: 36901603)
Schizophr Res. 2004 Nov 1;71(1):65-76. (PMID: 15374574)
Psychiatr Pol. 2021 Apr 30;55(2):261-274. (PMID: 34365478)
J Ultrasound Med. 2010 Mar;29(3):427-44. (PMID: 20194938)
Lancet. 2009 Aug 22;374(9690):635-45. (PMID: 19700006)
Curr Opin Psychiatry. 2019 Sep;32(5):388-393. (PMID: 31135491)
CNS Neurol Disord Drug Targets. 2022;21(4):302-315. (PMID: 34433406)

Keywords: cavum septi pellucidi; negative symptoms of schizophrenia; positive symptoms of schizophrenia; risk factors; schizophrenia

Date Created: 20230311 Date Completed: 20230314 Latest Revision: 20230326

20230327

PMC10001938

10.3390/ijerph20054592

36901603